What is Mind Cure Health Inc. (MCURF)?

Mind Cure Health Inc. (MCURF) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of MCURF?

The current price of MCURF is $0.51. Prices are updated in real time on Stocks360.

What is MCURF's price-to-earnings (PE) ratio?

MCURF's trailing twelve-month PE ratio is -4.72, based on current price and earnings per share data available on Stocks360.

What is MCURF's market capitalization?

MCURF's market capitalization is $86,531,198.00, placing it in the small-cap tier.

Mind Cure Health Inc. (MCURF)

Stock analysis · OTC · Healthcare · Biotechnology

$0.51

Market Cap

$86.53M

PE (TTM)

-4.72

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

-0.26

Day Range

$0.20 – $0.51

52-wk Range

$0.01 – $0.51

Avg Volume

N/A

Volume

11.50K

Mind Cure Health Inc. (MCURF) is a publicly traded company in the Healthcare sector. Latest price: $0.51. Market cap $86.53M. Trailing PE -4.72. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Proprietary Signals

Signal snapshot temporarily unavailable.

About Mind Cure Health Inc.

Mind Cure Health Inc., founded in Vancouver, Canada, in 2020, is a life sciences firm dedicated to improving mental health and wellness. The company develops and commercializes innovative products across North America, concentrating its efforts on pioneering digital therapeutics technology and exploring psychedelic compounds. This strategic approach aims to significantly broaden the availability of scientifically validated and evidence-based mental health treatments. Key offerings include iSTRYM, a distinctive digital therapeutics software designed to optimize the healing process for both patients and clinicians at all stages of therapy. Mind Cure also provides PsyCollage, a bioinformatics platform that helps prioritize research endeavors, and produces synthetic ibogaine to support researchers and medical professionals. Additionally, the company is investigating various psychedelic compounds, suchibogaine, for potential applications in treating traumatic brain injuries and related disorders.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-4.72×
P/S (TTM)	0.00×
P/B	9.35×
P/FCF (TTM)	-12.28×
EV / EBITDA	-19.04×
EV / Sales	0.00×
Earnings Yield	-21.29%
Free Cash Flow Yield	-8.14%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$112.05M
Net Income (TTM)	-$25.72M
Free Cash Flow (TTM)	-$9.83M
Net Debt	-$8.71M
Working Capital	$7.10M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-102.08%
Return on Invested Capital	-82.99%